Clinical trials · Texas
Lymphoma clinical trials in Texas
We’re tracking 165 recruiting lymphoma studies with a site in Texas — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Texas
- NCT04745949RecruitingPhase 2
Testing first-line antibody plus immunotherapy for mediastinal lymphoma
This trial tests a combination of antibody therapy and immunotherapy (plus standard chemo) as first treatment for primary mediastinal large B-cell lymphoma. It may help shrink the lymphoma and improve how long patients stay in remission.
Houston, TexasAges 18 years+ - NCT03011814RecruitingPhase 1/Phase 2
Durvalumab plus lenalidomide for relapsed T-cell lymphoma
This study tests a combination of two drugs—durvalumab (an immunotherapy) and lenalidomide (a targeted therapy)—to see if they are safe and effective for people with T-cell lymphoma that has come back or not responded to treatment. It aims to harness your immune system to fight the cancer while also attacking the cancer cells directly.
Houston, TexasAges 18 years+ - NCT05826535RecruitingPhase 1/Phase 2
Test of CAR T-cell therapy for aggressive B-cell lymphoma
This Phase 1/2 study tests a lab-made immune cell treatment (CAR T cells) made from your own blood cells to treat aggressive large B-cell lymphoma that has come back or didn’t respond. If you qualify, the goal is to see whether this treatment is safe and can shrink lymphoma.
Dallas, TexasAges 18 years+ - NCT06022029RecruitingPhase 1
Study of injected ONM-501 alone or with cemiplimab for advanced cancers
This trial tests an injected study drug (ONM-501) alone or with another drug (cemiplimab) for people with advanced solid tumors or lymphomas that haven't responded to other treatments. It aims to find a safe dose and see if the combination helps shrink or control the cancer.
Houston, TexasAges 18 years+ - NCT01371630RecruitingPhase 1/Phase 2
Inotuzumab plus chemotherapy for certain types of childhood-like leukemia
This early-phase trial studies how well a targeted drug (inotuzumab ozogamicin) combined with chemotherapy treats acute lymphoblastic leukemia (ALL). It may help people with newly diagnosed ALL who may not tolerate standard intensive chemotherapy, especially older adults.
Houston, TexasAges 18 years+ - NCT05886036RecruitingPhase 2
Comparing rituximab vs mosunetuzumab for NLPHL
This trial compares two immunotherapy drugs, rituximab and mosunetuzumab, to see which works better for people with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) who need treatment. It's for both newly diagnosed and previously treated patients.
Houston, TexasAges 18 years+ - NCT05334069Recruiting
Blood test study for early cancer detection in patients
This study collects blood from people with cancer and people without cancer (or with possible cancer) to test whether new blood tests can detect cancer earlier. Your blood samples help researchers evaluate how well these tests work.
Amarillo, TexasAges 40–75 - NCT07424833RecruitingPhase 1
Study of APG-3288 for Relapsed/Refractory Blood Cancers
This trial is testing a new drug called APG-3288 for people with certain relapsed or treatment-resistant blood cancers (like CLL/SLL, DLBCL, MCL, WM, MZL, or FL). You may qualify if you've tried at least 2 prior treatments and are looking for a new option.
Houston, TexasAges 18 years+ - NCT06564038RecruitingPhase 1/Phase 2
Study of AZD0486 alone or with other drugs for B-cell cancers
This trial tests a new drug called AZD0486, alone or with other medicines, for people with certain types of B-cell cancers that have come back or not responded to treatment. The goal is to see how safe and effective it is.
Houston, TexasAges 18 years+ - NCT03452774Recruiting
AI matches your cancer tests to possible treatment trials
This trial uses an AI system to help match people with certain cancer types and specific tumor test results (like gene or protein markers) to relevant clinical trials. It may help you and your doctor find studies that fit your cancer biology faster.
Dallas, TexasAges Any age - NCT05476770RecruitingPhase 1
Tagraxofusp for children with CD123-positive leukemia
This study tests tagraxofusp, a medicine that targets a marker called CD123 on cancer cells, in children and young adults whose leukemia or lymphoma has come back or is resistant to treatment. It may help by shrinking the cancer and improving disease control after standard therapies have not worked.
Houston, TexasAges 1–21 - NCT05512390RecruitingPhase 1
Test drug ABBV-319 in B-cell blood cancers
This Phase 1 trial studies ABBV-319 given by vein to see what side effects it causes and how the cancer activity changes in certain B-cell blood cancers. It may help people with relapsed or treatment-resistant disease by exploring new treatment options and better understanding how the drug moves through the body.
Dallas, TexasAges 18 years+ - NCT06137144RecruitingPhase 1/Phase 2
Study of AZD3470 for blood cancers alone or with other drugs
This trial tests a new drug called AZD3470, given alone or with other cancer treatments, for people with certain types of lymphoma (Hodgkin's lymphoma or T-cell lymphoma). It aims to see if the drug is safe and effective for patients who have already tried other treatments.
Houston, TexasAges 12 years+ - NCT01804686RecruitingPhase 3
Long-term ibrutinib follow-up with or without nivolumab
This study looks at how safe and effective ibrutinib is over the long term, either alone or together with nivolumab. You may join if you are already in an earlier ibrutinib study and your care team feels staying on ibrutinib is worth the risk.
Houston, TexasAges 18 years+ - NCT05947851RecruitingPhase 3
Nemtabrutinib plus venetoclax versus standard add-on therapy
This Phase 3 study tests whether adding nemtabrutinib to venetoclax works better than the usual next treatment approach (venetoclax plus rituximab) in people with relapsed or treatment-resistant CLL/SLL. It may help by improving how well the cancer responds after at least one prior therapy.
Sugar Land, TexasAges 18 years+ - NCT06337318RecruitingPhase 3
Comparing two drugs for low-tumor burden follicular lymphoma
This trial compares a standard drug called rituximab to a newer medicine called mosunetuzumab for people with a slow-growing type of lymphoma that is not causing many symptoms. The goal is to see if mosunetuzumab works better and has fewer side effects.
Houston, TexasAges 18 years+ - NCT04104776RecruitingPhase 1/Phase 2
Test drug tulmimetostat for advanced cancers and lymphomas
This early-phase study tests tulmimetostat (DZR123) to shrink or control advanced solid tumors and certain lymphomas, and it may also test a combination in some prostate cancer groups. If you qualify, you’ll receive the study drug and be monitored closely, including blood tests and a request for tumor tissue to look for biomarkers.
San Antonio, TexasAges 18 years+ - NCT06526793RecruitingPhase 2
Surovatamig for relapsed or refractory B-cell lymphoma
This trial tests a new drug, surovatamig, for people with certain types of non-Hodgkin lymphoma that have come back or not responded to at least two prior treatments. The goal is to see if the drug can shrink tumors and help patients.
Austin, TexasAges 18 years+ - NCT05092451RecruitingPhase 1/Phase 2
CD70-targeting NK cell therapy for blood cancer relapse
This study tests an immune therapy made from cord blood “NK cells” that are engineered to attack cells with a marker called CD70. It’s given after chemotherapy that reduces your blood and immune system, aiming to treat relapse or refractory (not responding) blood cancers.
Houston, TexasAges 12–80 - NCT04169737RecruitingPhase 2
Acalabrutinib and venetoclax for high-risk CLL or SLL
This trial tests whether acalabrutinib and venetoclax (with or without early obinutuzumab) can control chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It is mainly for people whose disease is high-risk, has come back, or did not respond to earlier treatment.
Houston, TexasAges 18 years+ - NCT07082803RecruitingPhase 1
TLN-121 for relapsed or refractory non-Hodgkin lymphomas
This trial tests a new drug called TLN-121 for people with certain types of non-Hodgkin lymphoma that have come back or not responded to previous treatments. It aims to see if the drug is safe and effective.
Houston, TexasAges 18 years+ - NCT03328078RecruitingPhase 1/Phase 2
Emavusertib for recurrent brain lymphoma after prior treatment
This Phase 1/2 trial tests emavusertib (a targeted medicine) in adults with primary central nervous system lymphoma that has come back or not responded to treatment. It’s designed to find safe dosing and see how well the treatment can control the lymphoma in the brain/spinal fluid.
Houston, TexasAges 18 years+ - NCT03666000RecruitingPhase 1
Testing a CD19 CAR T cell treatment for relapsed blood cancers
This Phase 1 study tests the safety and best dose of a CD19 CAR T cell therapy (azer-cel) in people whose B-cell blood cancer has returned or did not respond to treatment. It may help people with relapsed/refractory B-ALL or certain aggressive or large B-cell lymphomas, including after or before prior CAR T treatment.
Houston, TexasAges 18 years+ - NCT04288726RecruitingPhase 1
CAR T-cell trial for CD30-positive lymphomas that came back
This early-phase study tests a donor-made immune cell treatment designed to attack CD30-positive lymphomas that are relapsed or refractory. If you qualify, it could help by finding a safer, effective way to control the lymphoma using engineered T-cells.
Houston, TexasAges 12–75
Lymphoma trials by city in Texas
Where these studies are running in Texas
Institutions with a site for the recruiting lymphoma studies listed above.
- The University of Texas MD Anderson Cancer Center · 14 studies
- Research Site · 3 studies
- University of Texas Health Science Center at San Antonio · 3 studies
- University of Texas Southwestern Medical Center · 3 studies
- Baylor University Medical Center · 2 studies
- Audie L Murphy VA Hospital
- Baylor Charles A. Sammons Cancer Center
- Baylor College of Medicine
What taking part in a lymphoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Lymphoma trials in other states
Common questions
- Are there lymphoma clinical trials in Texas?
- Yes. We're currently tracking 165 recruiting lymphoma studies with a site in Texas, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a lymphoma study in Texas?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Texas to take part?
- Not necessarily. These studies have a site in Texas, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a lymphoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New lymphoma studies open in Texas regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.